Advertisement

HSS Journal ®

, Volume 13, Issue 1, pp 75–80 | Cite as

Commercial Separation Systems Designed for Preparation of Platelet-Rich Plasma Yield Differences in Cellular Composition

  • Ryan M. DegenEmail author
  • Johnathan A. Bernard
  • Kristin S. Oliver
  • Joshua S. Dines
Original Article

Abstract

Background

The role of platelet-rich plasma (PRP) in the treatment of sport-related injuries is unclear, largely due to the heterogeneity of clinical results. This may relate to compositional differences in PRP from different separation systems.

Questions/Purposes

This study aims to compare the composition of PRP produced with five different commercially available systems, focusing on cellular concentrations and pH.

Methods

Seven donors (41 ± 12 years) provided blood for PRP preparation using five systems (Arthrex Angel, Emcyte Genesis CS, Arteriocyte Magellan, Harvest SmartPrep, and Biomet GPS III). Post processing, cellular composition was measured including platelets (PLT), white blood cells (WBC), neutrophils (NE), and red blood cells (RBC), as well as pH.

Results

Platelet concentration and capture efficiency were similar between systems, except the Angel 7% preparation had a greater concentration than Genesis CS (2310 ± 524 vs. 1129 ± 264 k/μL). WBC concentration was variable between systems; however, significant differences were only found between the Angel 2% and GPS III preparations (11.0 ± 4.5, 27.3 ± 7.1 k/μL). NE concentration was significantly lower in the Angel 2% and 7% preparations compared with GPS III (0.6 ± 0.6 and 1.8 ± 1.3 k/μL vs. 9.4 ± 7.0 k/μL). RBC concentration was highest in SmartPrep (3.2 ± 0.6 M/μL) and Genesis CS systems (3.1 ± 0.6 M/μL) compared with all other systems (≤1.1 ± 1.2 M/μL). Finally, pH was significantly lower with the SmartPrep system (6.95 ± 0.06) compared with all others (≥7.26 ± 0.06).

Conclusion

Aside from platelet concentration and capture efficiency, significant compositional differences were identified between preparation systems. Caution should be employed when interpreting clinical results of studies utilizing PRP, as the role of compositional differences and their effect on outcome are unknown. Further study is necessary to determine the clinical significance of these differences.

Keywords

platelet-rich plasma platelet-rich plasma separation system cellular concentration 

Notes

Compliance with Ethical Standards

Conflict of Interest

Ryan M. Degen, MD, Johnathan A. Bernard, MD, and Kristin S. Oliver, MD have declared that they have no conflict of interest. Joshua S. Dines, MD reports personal fees from Arthrex, Conmed Linvatec and Ossur, outside the work.

Human/Animal Rights

All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2008 (5).

Informed Consent

Informed consent was obtained from all patients for being included in the study.

Required Author Forms

Disclosure forms provided by the authors are available with the online version of this article.

Supplementary material

11420_2016_9519_MOESM1_ESM.pdf (1.2 mb)
ESM 1 (PDF 1224 kb)
11420_2016_9519_MOESM2_ESM.pdf (1.2 mb)
ESM 2 (PDF 1224 kb)
11420_2016_9519_MOESM3_ESM.pdf (1.2 mb)
ESM 3 (PDF 1224 kb)
11420_2016_9519_MOESM4_ESM.pdf (1.2 mb)
ESM 4 (PDF 1224 kb)

References

  1. 1.
    Anitua E, Zalduendo MM, Prado R, Alkhraisat MH, Orive G (2015) Morphogen and proinflammatory cytokine release kinetics from PRGF-Endoret fibrin scaffolds: Evaluation of the effect of leukocyte inclusion. J. Biomed. Mater. Res. A 103:1011–1020.Google Scholar
  2. 2.
    Braun HJ, Kim HJ, Chu CR, et al. The Effect of Platelet-Rich Plasma Formulations and Blood Products on Human Synoviocytes: Implications for Intra-articular Injury and Therapy. Am J Sports Med. 2014; 42: 1204-1210.CrossRefPubMedGoogle Scholar
  3. 3.
    Castillo TN, Pouliot MA, Kim HJ, et al. Comparison of growth factor and platelet concentration from commercial platelet-rich plasma separation systems. Am J Sports Med. 2011; 39: 266-71.CrossRefPubMedGoogle Scholar
  4. 4.
    Cavallo C, Filardo G, Mariani E, et al. Comparison of platelet-rich plasma formulations for cartilage healing: an in vitro study. J Bone Joint Surg Am. 2014; 96: 423-9.CrossRefPubMedGoogle Scholar
  5. 5.
    Cepeda MS, Tzortzopoulou A, Thackrey M, Hudcova J, Arora Gandhi P, Schumann R (2012) Cochrane Review: Adjusting the pH of lidocaine for reducing pain on injection. Evidence-Based Child Heal. 7:149–215.Google Scholar
  6. 6.
    Cervellin M, de Girolamo L, Bait C, et al. Autologous platelet-rich plasma gel to reduce donor-site morbidity after patellar tendon graft harvesting for anterior cruciate ligament reconstruction: a randomized, controlled clinical study. Knee Surg Sports Traumatol Arthrosc. 2012; 20: 114-20.CrossRefPubMedGoogle Scholar
  7. 7.
    Dhurat R, Sukesh M. Principles and methods of preparation of platelet-rich plasma: A review and author’s perspective. J Cutan Aesthet Surg. 2014; 7: 189.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Dohan Ehrenfest DM, Andia I, Zumstein MA, et al. Classification of platelet concentrates (Platelet-Rich Plasma-PRP, Platelet-Rich Fibrin-PRF) for topical and infiltrative use in orthopedic and sports medicine: current consensus, clinical implications and perspectives. Muscles Ligaments Tendons J. 2014; 4: 3-9.PubMedPubMedCentralGoogle Scholar
  9. 9.
    Foster TE, Puskas BL, Mandelbaum BR, et al. Platelet-rich plasma: from basic science to clinical applications. Am J Sports Med. 2009; 37: 2259-72.CrossRefPubMedGoogle Scholar
  10. 10.
    Frank SG, Lalonde DH. How acidic is the lidocaine we are injecting, and how much bicarbonate should we add? Can J Plast Surg. 2012; 20: 71-73.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Giovanini AF, Deliberador TM, Tannuri Nemeth JE, et al. Leukocyte-platelet-rich plasma (L-PRP) impairs the osteoconductive capacity of the autograft associated to changes in the immunolocalization of TGF-β1 and its co-expression with Wnt10b and CD34 cells. J Craniomaxillofac Surg. 2013; 41: e180-6.CrossRefPubMedGoogle Scholar
  12. 12.
    Hall MP, Band PA, Meislin RJ, et al. Platelet-rich plasma: current concepts and application in sports medicine. J Am Acad Orthop Surg. 2009; 17: 602-8.CrossRefPubMedGoogle Scholar
  13. 13.
    Hsu WK, Mishra A, Rodeo SA, et al. Platelet-rich plasma in orthopaedic applications: evidence-based recommendations for treatment. J Am Acad Orthop Surg. 2013; 21: 739-48.PubMedGoogle Scholar
  14. 14.
    Jenis LG, Banco RJ, Kwon B (2006) A prospective study of Autologous Growth Factors (AGF) in lumbar interbody fusion. Spine J. 6:14–20.Google Scholar
  15. 15.
    Li G-Y, Yin J-M, Ding H, et al. Efficacy of leukocyte- and platelet-rich plasma gel (L-PRP gel) in treating osteomyelitis in a rabbit model. J Orthop Res. 2013; 31: 949-56.CrossRefPubMedGoogle Scholar
  16. 16.
    Lopez-Vidriero E, Goulding KA, Simon DA, et al. The use of platelet-rich plasma in arthroscopy and sports medicine: optimizing the healing environment. Arthroscopy. 2010; 26: 269-78.CrossRefPubMedGoogle Scholar
  17. 17.
    Marx RE. Platelet-rich plasma (PRP): what is PRP and what is not PRP? Implant Dent. 2001; 10: 225-8.CrossRefPubMedGoogle Scholar
  18. 18.
    Mazzocca AD. Platelet-Rich Plasma Differs According to Preparation Method and Human Variability. J Bone Jt Surg. 2012; 94: 308.CrossRefGoogle Scholar
  19. 19.
    Mazzocca AD, McCarthy MBR, Chowaniec DM, et al. Platelet-rich plasma differs according to preparation method and human variability. J Bone Joint Surg Am. 2012; 94: 308-16.CrossRefPubMedGoogle Scholar
  20. 20.
    Mazzucco L, Balbo V, Cattana E, et al. Not every PRP-gel is born equal. Evaluation of growth factor availability for tissues through four PRP-gel preparations: Fibrinet, RegenPRP-Kit, Plateltex and one manual procedure. Vox Sang. 2009; 97: 110-8.CrossRefPubMedGoogle Scholar
  21. 21.
    McCarrel TM, Minas T, Fortier LA. Optimization of leukocyte concentration in platelet-rich plasma for the treatment of tendinopathy. J Bone Joint Surg Am. 2012; 94: e143(1–8).CrossRefGoogle Scholar
  22. 22.
    McCarthy ML, MacKenzie EJ, Edwin D, et al. Psychological distress associated with severe lower-limb injury. J Bone Joint Surg Am. 2003; 85-A: 1689-97.CrossRefPubMedGoogle Scholar
  23. 23.
    Mishra A, Pavelko T. Treatment of chronic elbow tendinosis with buffered platelet-rich plasma. Am J Sports Med. 2006; 34: 1774-8.CrossRefPubMedGoogle Scholar
  24. 24.
    Mishra AK, Skrepnik NV, Edwards SG, et al. Efficacy of platelet-rich plasma for chronic tennis elbow: a double-blind, prospective, multicenter, randomized controlled trial of 230 patients. Am J Sports Med. 2014; 42: 463-71.CrossRefPubMedGoogle Scholar
  25. 25.
    Moojen DJF, Everts PAM, Schure R-M, et al. Antimicrobial activity of platelet-leukocyte gel against Staphylococcus aureus. J Orthop Res. 2008; 26: 404-10.CrossRefPubMedGoogle Scholar
  26. 26.
    Nikolidakis D, Jansen JA. The biology of platelet-rich plasma and its application in oral surgery: literature review. Tissue Eng Part B Rev. 2008; 14: 249-58.CrossRefPubMedGoogle Scholar
  27. 27.
    Nin JRV, Gasque GM, Azcárate AV, et al. Has platelet-rich plasma any role in anterior cruciate ligament allograft healing? Arthroscopy. 2009; 25: 1206-13.CrossRefPubMedGoogle Scholar
  28. 28.
    Parham SM, Pasieka JL. Effect of pH modification by bicarbonate on pain after subcutaneous lidocaine injection. Can J Surg. 1996; 39: 31-35.PubMedPubMedCentralGoogle Scholar
  29. 29.
    Peerbooms JC, Sluimer J, Bruijn DJ, et al. Positive effect of an autologous platelet concentrate in lateral epicondylitis in a double-blind randomized controlled trial: platelet-rich plasma versus corticosteroid injection with a 1-year follow-up. Am J Sports Med. 2010; 38: 255-62.CrossRefPubMedGoogle Scholar
  30. 30.
    Portela GS, Cerci DX, Pedrotti G, et al. L-PRP diminishes bone matrix formation around autogenous bone grafts associated with changes in osteocalcin and PPAR-γ immunoexpression. Int J Oral Maxillofac Surg. 2014; 43: 261-8.CrossRefPubMedGoogle Scholar
  31. 31.
    Sánchez M, Anitua E, Azofra J, et al. Comparison of surgically repaired Achilles tendon tears using platelet-rich fibrin matrices. Am J Sports Med. 2007; 35: 245-51.CrossRefPubMedGoogle Scholar
  32. 32.
    Sánchez M, Fiz N, Azofra J, et al. A randomized clinical trial evaluating plasma rich in growth factors (PRGF-Endoret) versus hyaluronic acid in the short-term treatment of symptomatic knee osteoarthritis. Arthroscopy. 2012; 28: 1070-8.CrossRefPubMedGoogle Scholar
  33. 33.
    Saucedo JM, Yaffe MA, Berschback JC, et al. Platelet-rich plasma. J Hand Surg Am. 2012; 37: 587-9. quiz 590.CrossRefPubMedGoogle Scholar
  34. 34.
    Sheth U, Simunovic N, Klein G, et al. Efficacy of autologous platelet-rich plasma use for orthopaedic indications: a meta-analysis. J Bone Joint Surg Am. 2012; 94: 298-307.CrossRefPubMedGoogle Scholar

Copyright information

© Hospital for Special Surgery 2016

Authors and Affiliations

  • Ryan M. Degen
    • 1
    Email author
  • Johnathan A. Bernard
    • 1
  • Kristin S. Oliver
    • 2
  • Joshua S. Dines
    • 1
  1. 1.Sports Medicine and Shoulder Service, Hospital for Special SurgeryNew YorkUSA
  2. 2.Blue Tail Medical GroupSt LouisUSA

Personalised recommendations